Pharmaceuticals

Eton Pharmaceuticals

Eton Pharmaceuticals released FY2026 Q1 earnings on May 14 After-Market (EST), actual revenue USD 24.27 M (forecast USD 22.4 M), actual EPS USD 0.05 (forecast USD 0.09)

Eton Pharmaceuticals to release FY2026 Q1 earnings on May 14 After-Market EST, forecast revenue USD 22.4 M, EPS USD 0.09

Eton Pharmaceuticals released FY2025 Q4 earnings on March 19 After-Market EST, actual revenue USD 21.28 M (forecast USD 20.58 M), actual EPS USD 0.0515 (forecast USD 0.1033)

Eton Pharmaceuticals released FY2025 earnings on March 19 After-Market EST, actual revenue USD 79.95 M (forecast USD 79.27 M), actual EPS USD -0.1709 (forecast USD -0.1166)

Eton Pharmaceuticals to release FY2025 Q4 earnings on March 19 After-Market EST, forecast revenue USD 20.58 M, EPS USD 0.1033

Eton Pharmaceuticals released FY2025 9 Months Earnings on November 6 After-Market EST, actual revenue USD 58.67 M, actual EPS USD -0.2316

Eton Pharmaceuticals released FY2025 Q3 earnings on November 6 After-Market (EST), actual revenue USD 22.46 M (forecast USD 20.47 M), actual EPS USD -0.0716 (forecast USD 0.09)

Eton Pharmaceuticals to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 20.47 M, EPS USD 0.09

Eton Pharmaceuticals released FY2025 Semi-Annual earnings on August 7 After-Market (EST), actual revenue USD 36.21 M, actual EPS USD -0.1545

Eton Pharmaceuticals released FY2025 Q2 earnings on August 7 After-Market EST, actual revenue USD 18.93 M (forecast USD 16.71 M), actual EPS USD -0.1 (forecast USD -0.0366)

Eton Pharmaceuticals to Release FY2025 Q2 Earnings on August 7 After-Market EST, Forecast Revenue USD 16.71 M, EPS USD -0.0366

Eton Pharmaceuticals' New Drug Application Accepted by FDA

Eton Pharmaceuticals Inc. to be included in Russell 2000® and Russell 3000® indices

Eton Pharmaceuticals Releases Corporate Presentation

Eton Pharmaceuticals' COO Disposes Common Stock

Opaleye Management Reports Acquisition of Eton Pharmaceuticals Common Stock

Eton Pharmaceuticals Inc. holds annual shareholders' meeting

Eton Pharmaceuticals CEO Reports Stock Disposal

Eton Pharmaceuticals' KHINDIVI™ Oral Solution Approved by FDA

Eton Pharmaceuticals Announces CEO Changes

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

ETON

LABU

ARKG

UBS Group AG reduced its stake in Eton Pharmaceuticals, Inc. by 42.5% in Q4, owning 126,674 shares worth $2.14 million. Other institutional investors, including Millennium Management and Goldman Sachs, increased their stakes. Insider David Krempa sold 19,679 shares, reducing his ownership by 43.80%. Analysts have mixed ratings on ETON, with a consensus rating of 'Hold' and an average target price of $41.00. Eton's shares opened at $32.40, with a market cap of $887.44 million.

Market Beat

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

iShares US Pharma

SPDR S&P Biotech

UBS Group AG

Goldman Sachs

JPMorgan Chase

Legal & General Group Plc

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

Eton Pharmaceuticals, Inc. $ETON Shares Sold by UBS Group AG

SBIO

David Krempa, Chief Business Officer of Eton Pharmaceuticals, sold shares worth $3.2 million, with transactions executed at prices between $31.47 and $33.88 per share. The sales occurred on May 22, 26, and 27, 2026, totaling $3,229,923. Post-sale, Krempa retains 25,249 shares of common stock.

TradingView

Health Care Select Sector SPDR

VG Health

ALPS Medical Breakthrough

Eton Pharmaceuticals Chief Business Officer Sold Shares Worth Over $3.2M

IBBQ

Eton Pharmaceuticals has secured exclusive U.S. rights to IMPAVIDO, the only FDA-approved oral therapy for leishmaniasis, set for launch on September 26, 2026. This agreement enhances Eton's rare-disease portfolio, which includes ten marketed products and four in late-stage development. CEO Sean Brynjelsen emphasized IMPAVIDO's critical role in their orphan-focused model. Eton's stock closed at $32.89, up 1.23%, and rose to $33.91 in after-hours trading.

nasdaq

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Nasdaq

Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million.

iShares Global Healthcare

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

Eton Pharmaceuticals reported a 73% year-over-year increase in product revenue, reaching $24 million in Q1 2026. The company launched two new products and raised its full-year revenue guidance to exceed $120 million. Adjusted EBITDA for the quarter was $5.7 million, with a target of a 30% margin for the year and 50% by 2028. Eton is focusing on R&D projects and acquisitions to expand its rare disease portfolio, aiming for $200 million in annual revenue by 2027 and $500 million by 2030.

Eton Pharmaceuticals(ETON.US)

Eton Pharmaceuticals, Inc. $ETON Shares Sold by UBS Group AG

Eton Pharmaceuticals Chief Business Officer Sold Shares Worth Over $3.2M

Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

Full Transcript: Eton Pharmaceuticals Q1 2026 Earnings Call

Eton Pharmaceuticals | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 24.27 M

Eton Pharmaceuticals | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 24.27 M